CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Association of loop diuretics use and dose with outcomes in outpatients with heart failure: a systematic review and meta-analysis of observational studies involving 96,959 patients Cardiac Resynchronization Therapy and Ventricular Tachyarrhythmia Burden Association of Reduced Apical Untwisting With Incident HF in Asymptomatic Patients With HF Risk Factors A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics Sodium-Glucose Co-Transporter 2 Inhibitors and Insights from Biomarker Measurement in Heart Failure Patients A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure H2FPEF Score for Predicting Future Heart Failure in Stable Outpatients With Cardiovascular Risk Factors
|<<... 10 11 12 13 14 15 16 ...>>|

Original Research2021 Jan 10;S1547-5271(21)00009-6.

JOURNAL：Heart Rhythm. Article Link

Cardiac Resynchronization Therapy and Ventricular Tachyarrhythmia Burden

S Tankut, I Goldenberg, V Kutyifa et al. Keywords: cardiac resynchronization therapy; heart failure; left bundle branch block; ventricular fibrillation; ventricular tachycardia arrhythmia.

ABSTRACT

BACKGROUND - Cardiac resynchronization therapy-defibrillator (CRT-D) may reduce the incidence of first ventricular tachyarrhythmia (VTA) in patients with heart failure (HF) and left bundle-branch-block (LBBB).

 

OBJECTIVE - To assess the effect of CRT-D on VTA burden in LBBB patients.

 

METHODS - We included 1281 patients with LBBB from MADIT-CRT. VTA was defined as any treated or monitored sustained ventricular tachycardia (VT≥180 bpm) or ventricular fibrillation (VF). Life-threatening VTA was defined as VT≥200 bpm or VF. VTA recurrence was assessed using the Andersen-Gill model.

 

RESULTS - During a mean follow-up of 2.5 years, 964 VTA episodes occurred in 264 (21%) patients. The VTA rate per 100 person-years was significantly lower in the CRT-D group when compared with the ICD group (20 vs. 34; respectively; p<0.01). Multivariate analysis demonstrated that CRT-D treatment was associated with a 32% risk reduction for VTA recurrence (HR=0.68; 95%CI 0.57-0.82; p<0.001), 57% risk reduction for recurrent life-threatening VTA, 54% risk reduction for recurrent appropriate ICD-shocks, and a 25% risk reduction for the combined endpoint of VTA and death. The effect of CRT on VTA burden was consistent among all tested subgroups, but was more pronounced among NYHA class I patients. Landmark analysis showed that at 2 years, the cumulative probability of death subsequent to year one was highest (16%) among patients who had ≥2 VTA events during their first year.

 

CONCLUSION - In patients with LBBB and HF, early intervention with CRT-D reduces mortality, VTA burden, and frequency of multiple appropriate ICD shocks. VTA burden is a powerful predictor of subsequent mortality.

 

 

>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top